Journal
JOURNAL OF INTEGRATIVE NEUROSCIENCE
Volume 20, Issue 2, Pages 321-329Publisher
IMR PRESS
DOI: 10.31083/j.jin2002031
Keywords
beta-hydroxybutyric acid; Apoptosis; Mitochondrial function; Oxidative stress; Neuro-protection; Cognitive enhancer; Computational analysis
Categories
Funding
- Auburn University
Ask authors/readers for more resources
Research has shown that beta-hydroxybutyric acid has significant neuroprotective effects, reducing the risk of neurodegenerative diseases through antioxidant effects and improved mitochondrial function.
Ketone bodies have been the topic of research for their possible therapeutic neurotropic effects in various neurological diseases such as Parkinson's disease, dementia, and seizures. However, continuing research on ketone bodies as a prophylactic agent for decreasing the risk for various neurodegenerative diseases is currently required. In this paper, hippocampal HT-22 cells were treated with beta-hydroxybutyric acid at different doses to elucidate the neurotropic effects. In addition, markers of oxidative stress, mitochondrial function, and apoptosis were investigated. As a result, the ketone body (beta-hydroxybutyric acid) showed a significant increase in hippocampal neuronal viability at a moderate dose. Results show that beta-hydroxybutyric acid exhibited antioxidant effect by decreasing prooxidant oxidative stress markers such as reactive oxygen species, nitrite content, and increasing glutathione content leading to decreased lipid peroxidation. Results show that beta-hydroxybutyric acid improved mitochondrial functions by increasing Complex-I and Complex-IV activities and showing that beta-hydroxybutyric acid significantly reduces caspase-1 and caspase-3 activities. Finally, using computational pharmacokinetics and molecular modeling software, we validated the pharmacokinetic effects and pharmacodynamic (N-Methyl-D-aspartic acid and acetylcholinesterase) interactions of beta-hydroxybutyric acid. The computational studies demonstrate that beta-hydroxybutyric acid can interact with N-Methyl-D-aspartic acid receptor and cholinesterase enzyme (the prime pharmacodynamic targets for cognitive impairment) and further validates its oral absorption, distribution into the central nervous system. Therefore, this work highlights the neuroprotective potential of ketone bodies in cognitive-related neurodegenerative diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available